NY Attorney General Eric Schneiderman announced a record $181 million settlement with Janssen Pharmaceuticals and its parent company Johnson & Johnson to resolve charges of improper marketing and ...

On April 1, 2024 the Federal Circuit released its opinion in Janssen Pharmaceuticals, Inc. et al v. Teva Pharmaceuticals USA, Inc. et al., affirming the district court’s finding that certain claims ...

Sun Pharmaceutical Industries was hit with a patent infringement lawsuit on July 9 in New Jersey District Court over its attempt to market generic versions of the antipsychotic drug Invega Sustenna.

Janssen sued Teva in the US District Court for the District of New Jersey under the Hatch-Waxman Act after Teva filed an abbreviated new drug application (ANDA) on a generic version of Invega Sustenna ...

"With the closing of the NUCYNTA transaction, the transformation of Depomed into a leader in the pain and central nervous system market is now complete. We closed the deal ahead of our original ...

TITUSVILLE, N.J., April 3, 2017 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address an ...

“The CAFC first explained that the case law on presumption of obviousness due to overlapping numerical ranges between the patent at issue and the prior art did not support applying the presumption in ...

“Because ‘[w]hat matters is the objective reach of the claim,’…the district court erred to the extent it effectively defined its obviousness inquiry as one concerning the ‘generalized’ suitability of ...

UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the ...

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, was sued by Bayer AG for breach of contract on Oct. 16 in New York Southern District Court. The suit, brought by Selendy Gay, accuses the ...